Skip to content
Stamford Pharmaceuticals
  • Home
  • Who we are
  • Pipeline & Portfolio
  • Patients
    • Clinical Trials
    • Basal Cell Nevus Syndrome / Gorlin Syndrome
    • Cutaneous Squamous Cell Carcinoma
    • Cutaneous Breast Cancer
  • News
  • Career
Stamford Pharmaceuticals

Stamford Pharmaceuticals announces the first patient on-study to be treated with ASN-002

Posted August 13, 2020August 13, 2020 spa

Stamford Pharmaceuticals Inc and Ascend Biopharmaceuticals Ltd (its Australian affiliate) announces the first patient on-study to be treated with ASN-002 […]

Stamford Pharmaceuticals Inc Announces Clinical Collaboration with Roche

Posted April 1, 2020April 13, 2020 spa

Stamford Pharmaceuticals Inc Announces Clinical Collaboration with Roche to Evaluate SP-002 in Combination with vismodegib in Patients with basal cell […]

Stamford Pharmaceuticals announced receiving HREC approval for the commencement of the initial phase of its registration program

Posted August 6, 2019August 7, 2019 spa

Stamford Pharmaceuticals announced today receiving ethics approval for the Pilot phase of its registration program. The program will commence initially […]

Stamford Pharmaceuticals announced today that Associate Professors Greg Siller and Sherrif Ibrahim will be Principal Investigators for the company’s initial Pilot phase of its registration program in Australia and the US

Posted August 1, 2019August 7, 2019 spa

August 1st, 2019 Stamford Pharmaceuticals announced today the engagement with Assoc. Professors Greg Siller and Sherrif Ibrahim to serve as […]

Stamford Pharmaceuticals

Stamford Pharmaceuticals Inc
Level 2, 330 Railroad Ave,
Greenwich, CT 06830

Ph.: 203-516-7895
Email: info@stamfordpharmaceuticals.com
Web: www.stamfordpharmaceuticals.com

Stamford Pharmaceuticals Inc © 2019 | Legal Notice